eligibility_summary
Adults ≥18 with relapsed/refractory CD20+ aggressive B‑cell lymphoma (DLBCL variants/HGBCL/PMBCL/FL3B), measurable disease, ECOG 0–1, adequate labs/organ function, ≥4 wks from anti‑CD20, ≥12 wks from CAR‑T, AEs ≤G1, steroids ≤10 mg/d, consent + contraception. Exclude CNS lymphoma, recent systemic therapy/checkpoint, RT or major surgery, significant cardiac disease, active infection/HIV/HBV/HCV, autoimmune disease needing tx, seizures on meds, recent transplant, live vaccines, pregnancy, pembro allergy, prior anti‑CD47, warfarin.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 study in relapsed/refractory DLBCL combining: 1) Maplirpacept (TTI‑622), a recombinant SIRPα‑IgG4 Fc fusion protein (biologic) that binds and blocks CD47 on tumor cells to inhibit the “don’t‑eat‑me” signal, unleashing macrophage/monocyte phagocytosis, 2) Pembrolizumab, an anti–PD‑1 monoclonal antibody (immunotherapy) that restores T‑cell activity. An earlier arm with ontorpacept (TTI‑621, SIRPα‑Fc fusion protein) plus pembrolizumab is closed. Targeted cells/pathways: CD47–SIRPα innate immune checkpoint on myeloid cells (macrophages/monocytes), and PD‑1/PD‑L1 adaptive checkpoint on T cells/TILs, tumor target is malignant CD20+ B cells (DLBCL and related entities). Correlatives: SIRPα expression, macrophage markers, TILs, PD‑1/PD‑L1. Aim: safety/RP2D and preliminary efficacy.